STUDboardsPlay · Research · Self · Fit · Money · Learn · Study · Plan · Token STUDtokenOptional

STUDresearch · Peptide

CagriSema

Also known as

CagriSema (cagrilintide + semaglutide) · cagrilintide/semaglutide combo · cagrilintide–semaglutide · Cagri Sema · cagri-sema · NN9838 + semaglutide coadministration (developmental discussion) · amylin + GLP-1 fixed-dose combination (Novo)

Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.

Open in the directory ↗
Peptide Lots of talk Systemic Subcutaneous Metabolic / GLP-1 class

Systemic — investigational cagrilintide plus semaglutide, studied for appetite, weight and glycemic effects; trial pens differ from gray blends.

What people say CagriSema is the investigational pairing of cagrilintide, a long-acting amylin analogue, with semaglutide, a GLP-1 receptor agonist. Trial devices and unverified research blends are not interchangeable. Doses people talk about
Phase 3 paired maintenance target2.4 mg cagrilintide + 2.4 mg semaglutide weekly

Investigational paired target after staged escalation in the obesity program.

REDEFINE paired study ladder0.25/0.25 → 0.5/0.5 → 1.0/1.0 → 1.7/1.7 → 2.4/2.4 mg

Approximately four-week trial stages with protocol flexibility; arrows describe the study design only.

Earlier phase 1b dose-findingCagrilintide 0.16–4.5 mg with semaglutide toward 2.4 mg weekly

Historical combination dose-finding, not the final paired phase 3 schedule.

Community separate-vial or blend mimicsVaried and unverified

Forum use does not reproduce the trial device; identity, ratio, fill, sterility, concentration and calculations remain uncertain.

The rows are study and discussion contexts, not a personal titration, missed-dose, mixing, or restart protocol.

Half-life & effect duration

Half-life in the body
  • Cagrilintide componentAbout 159–195 hours — roughly 6.6–8.1 days
  • Semaglutide componentAbout 145–165 hours — roughly 6–7 days
Felt duration people report
  • Early fullnessWithin about 6 hours in one blinded-trial account
  • During continued treatmentConstipation, fatigue or persistent nausea in other accounts
Timing context & sources
How it may feel Participant and forum accounts describe fullness, appetite suppression, nausea, constipation, reflux, fatigue, or brain fog, often around the first day or several days after a weekly dose. Blinding, component uncertainty, and product differences limit attribution.
Cycles people discuss REDEFINE 1/2 follow 68 weeks and REDEFINE 4 about 84 weeks; community plans mention 12–24-week runs or 8–12-week titration-only tests. Those shorter blocks do not reproduce long-trial outcomes or establish safe cycling. Timing Once-weekly trial administration is separate from morning/evening choices around nausea in forum reports. Smaller-meal and first-day fatigue discussions concern tolerability, not a validated timing strategy. Stacks The combination already contains two active agents. Adding other incretins or using separate-vial mimics makes dose, identity, and symptom attribution less reliable. Access talk Three shelves people mix up: investigational dual-chamber pen (trial/future brand), two separate research vials pinned same day, and pre-blended “CagriSema” / “CagriSema Sodium” lyophilized vials. Same nickname, not the same exposure. Watch for GI (most common): Nausea, vomiting, diarrhea, constipation, abdominal discomfort — class-typical, often titration-linked and mostly mild–moderate in trial summaries.
Related
CagrilintideSemaglutideTirzepatideRetatrutideSurvodutide

Tap a line to jump into the full notes. Research only — may be wrong.

Timing context & sources

Half-life in the body

The checked phase 1b study does not establish one combined-product half-life.

It measured cagrilintide at 159–195 hours and semaglutide at 145–165 hours after repeated co-administration.

Component-specific exploratory PK in a small phase 1b study cannot be collapsed into one combination value or a felt-duration rule.

Felt duration people report

The inspected accounts do not establish one dependable post-dose felt window.

A blinded first-week reporter described fullness within about six hours and later GI symptoms. Rubyslides described constipation and fatigue; Kurious_Kat_13 later described persistent nausea at 1.7 mg, while beach_is_life_12 was uncertain of the received component.

Blinding, uncertain treatment arm, small anecdotal sample, evolving dose, component ambiguity and unverified community products prevent a general clock.

  • CagriSema 1st week (opens in a new tab)Original post by a blinded trial participant: possible 0.25/0.25 combination, fullness and appetite change around six hours, then burps, hiccups and reflux over following days; treatment arm unknown.Blinded allocation could have been combination, semaglutide or placebo; one early participant account and short follow-up.
  • Calling all CagriSema brothers and sisters (opens in a new tab)Rubyslides described a fourth 0.25-stage injection with constipation and fatigue. Kurious_Kat_13 later described months at 1.7 mg with persistent nausea and a 2.4-mg update. beach_is_life_12 was unsure of the component and later said Mounjaro worked better.Anonymous self-described trial participation, evolving doses and limited verification; component uncertainty and a separate participant later randomized to Mounjaro prevent uniform CagriSema attribution.

Other context in this card

What people say 15

  • Appetite / food noise (community): Strong multi-pathway quieting of hunger and meal size vs high-dose sema alone is the main subjective sell; users describe earlier fullness and less grazing. forum
  • Off-drug / continuous use: Large losses generally need ongoing weekly exposure; regain expected after stop — same chronic-disease model as other incretin obesity drugs. forum
  • Body composition caveat: Scale loss is mostly fat but lean mass still falls with large absolute deficits; protein + resistance training is the default mitigation talk, not a proven unique CagriSema muscle-sparing claim. forum
  • REDEFINE 1 design (no T2D): 68-week Phase 3, n=3,417 adults with obesity or overweight + ≥1 comorbidity; randomized 21:3:3:7 to CagriSema 2.4/2.4 mg (n=2,108), semaglutide 2.4 mg (n=302), cagrilintide 2.4 mg (n=302), or placebo (n=705), all with lifestyle intervention. trial
  • REDEFINE 1 trial-product estimand (68 wk): ~22.7% mean weight loss with CagriSema vs ~16.1% semaglutide 2.4 mg, ~11.8% cagrilintide 2.4 mg, ~2.3% placebo — combo beat both monotherapies. trial
  • REDEFINE 1 treatment-policy estimand (68 wk): ~20.4% CagriSema vs ~14.9% sema, ~11.5% cagri, ~3.0% placebo (estimated difference vs placebo ~−17.3 percentage points). trial
  • BMI category shift (REDEFINE 1 supportive): ~50.7% of CagriSema participants with obesity reached non-obesity BMI <30 kg/m² from mean baseline BMI ~38 vs ~10.2% placebo. trial
  • REDEFINE 2 (T2D + overweight/obesity, 68 wk, n=1,206): Treatment-policy mean ~−13.7% vs ~−3.4% placebo; full-adherence / trial-product style summaries ~15.7% vs ~3.1% — smaller mean % loss than non-diabetes REDEFINE 1, consistent with other incretin obesity vs T2D patterns. trial
  • REIMAGINE 2 (T2D program, sponsor topline): Superior HbA1c reduction of ~1.91 percentage points and ~14.2% weight loss reported in Novo communications (detailed conference readout expected 2026). trial
  • REDEFINE 4 head-to-head (obesity, open-label, ~84 wk, n=809, mean baseline weight ~114.2 kg): CagriSema 2.4/2.4 vs tirzepatide 15 mg — efficacy estimand ~23.0% vs ~25.5%; treatment-regimen estimand ~20.2% vs ~23.6%. Prespecified noninferiority on percent weight loss was not met. trial
  • Phase 1b coadmin (Enebo et al., ~20 weeks): Cagrilintide stepped with semaglutide 2.4 mg; ~17.1% mean loss reported at higher combo cohorts vs smaller loss on sema + placebo — early signal of additivity. trial
  • Vs mono components: Active-control REDEFINE 1 arms are the cleanest “is the combo worth it?” data — mean loss stack ranks CagriSema > sema 2.4 > cagri 2.4 > placebo. trial
  • Deep responders (REDEFINE 1): ~40.4% reached ≥25% loss on CagriSema (trial-product framing) vs ~16.2% sema, ~6.0% cagri, ~0.9% placebo; coverage also cites ~60% ≥20% and ~23% ≥30% on the combo in some summaries. trial
  • Glycemic (REDEFINE 2): ~73.5% reached HbA1c ≤6.5% on CagriSema vs ~15.9% placebo (treatment-policy framing in public summaries). trial
  • Phase 2 T2D (Frias et al., ~32 weeks): Co-administered cagrilintide 2.4 + semaglutide 2.4 outperformed either monotherapy on weight in diabesity framing. trial

Doses people talk about 19

  • Forum mimic — separate vials: Threads describe two research products used on the same day or staggered by hours to imitate 1:1 paired exposure. Separate containers add ratio, concentration, identity, sterility and calculation uncertainty; no preparation method is supplied here. forum
  • Forum mimic — pre-blended research vials: Vendor “CagriSema” blends claim fixed 1:1 total mg; simplify one-injection logistics but lock ratio and inherit unknown purity/fill risk. forum
  • Independent titration debate: Separate vials let users hold cagri low while climbing sema (or reverse) if one component drives GI — not how the fixed dual-chamber trial pen works. forum
  • Uncertainty: Research vials and compounded stacks are not the dual-chamber trial product — identity, sterility, and true mg per vial are unverified without third-party testing. forum
  • Blended-vial uncertainty: Severe vomiting was reported after a first exposure to an unverified blend. Replies suspected decimal or unit errors, but the poster disputed the larger volume; delivered amount and cause remain unresolved. Product identity, fill, sterility and concentration add uncertainty. forum
  • Stay-split camp: Two vials let people hold cagri at 0.25–0.5 while sema sits at a familiar milligram — the point of not using a locked 1:1 blend. forum
  • Slow titrate / extra holds: Community often extends each step beyond 4 weeks or stays at 1.0/1.0 or 1.7/1.7 if satiety is strong or vomiting recurs — aligned with REDEFINE flexible-escalation spirit. forum
  • Missed-dose discussion: Some forum heuristics describe skipping near the next weekly day rather than doubling, alongside same-weekday habits borrowed from semaglutide culture. Practices vary; this is not an approved CagriSema patient-leaflet rule. forum
  • REDEFINE paired titration ladder (every ~4 weeks, both components together): Week 1–4: 0.25/0.25 mg → weeks 5–8: 0.5/0.5 mg → weeks 9–12: 1.0/1.0 mg → weeks 13–16: 1.7/1.7 mg → week 17+: 2.4/2.4 mg maintenance. trial
  • Titration length: ~16 weeks of co-escalation then multi-month maintenance (REDEFINE: ~52-week maintenance after escalation inside the 68-week treatment design, plus off-treatment follow-up in protocol descriptions). trial
  • Flexible dosing in protocol: Investigators could delay step-ups or reduce dose for adverse effects or if BMI entered a low-normal range with health concern; participants could remain on submaximum doses and still contribute to estimands. trial
  • Why only ~57% hit full dose: Tolerability-driven holds and reductions explain the gap between assigned target and actual end-of-trial dose — still large mean losses, so community “hold lower if food noise is already dead” mirrors trial practice. trial
  • Phase 1b combo bands: Early work co-escalated cagrilintide 0.16–4.5 mg with semaglutide toward 2.4 mg over ~16 weeks — historical dose-finding, not the final REDEFINE fixed schedule. trial
  • 2.4/7.2 is not a research-chem chart: 2026 sponsor talk of a higher-dose CagriSema trial (2.4 cagri / 7.2 sema) is a future study, not a DIY target. trial
  • Framing: Trial targets, protocol ladders, and community research-chem mimic talk only — discussed ranges, not medical advice, not approved labeling, not a recommendation to use. forum
  • Phase 3 maintenance target: Once-weekly subcutaneous cagrilintide 2.4 mg + semaglutide 2.4 mg (1:1 fixed pairing at full dose). trial
  • Lower fixed arms / diabetes designs: Some programs discuss or study lower paired levels (e.g., 1.0 mg + 1.0 mg style arms in diabetes development talk); 2.4/2.4 remains the obesity Phase 3 headline target. trial
  • Mono cagrilintide contrast: Phase 2 mono cagrilintide explored 0.3–4.5 mg weekly (high arm ~10.8% at 26 weeks); in the CagriSema fixed combo, cagrilintide is capped at 2.4 mg paired with sema 2.4 mg — do not assume mono 4.5 mg charts apply to the combo product. trial
  • Ceiling talk: Trial and community “full” is 2.4/2.4 weekly for the combo product; pushing cagri above 2.4 while on high-dose sema is mono-phase-2 lore, not REDEFINE CagriSema labeling. trial

How it may feel 12

  • Days 1–7: First satiety bump or mild nausea/fullness; long half-lives mean exposure is building, not a same-day stimulant peak. forum
  • Weeks 5–8 (0.5/0.5): First real step-up; nausea often re-flares — many community logs call early escalation the worst GI window. forum
  • Months 3–6: Steadier weekly loss if protein/training hold; plateau talk starts for some; dose holds below 2.4/2.4 remain common when satiety is already strong. forum
  • 0.25 is quiet, 0.5 is the sick step: Trial-arm and r/CagriSema logs both say the first paired 0.25/0.25 can feel like placebo, then 0.5/0.5 lights nausea within hours. forumtrial
  • Blended first month: 2025 pre-blend logs describe drowsiness weeks 1–3, then shot-day nausea, plus a day-after “blues.” Not a trial endpoint. anecdote
  • Food-baby bloating: Trial patients describe fullness without classic nausea at the low step — “I know it’s not placebo because I look six months pregnant after three bites.” forum
  • Independent-titration feel: Separate-vial logs that add 0.25 cagri onto an already-running sema or tirz often report more satiety than extra GI — the reverse of jumping both at 1.2 mg in one blend. forum
  • Weeks 1–4 (0.25/0.25 initiation): Early GI (nausea, fullness, bowel changes); quieter appetite often precedes large scale drops. Community and trial both treat this band as tolerability priority. trial
  • Weeks 9–16 (1.0/1.0 → 1.7/1.7): Meal size keeps shrinking; each 4-week climb can reintroduce GI; investigators in REDEFINE could delay escalation or reduce dose for AEs or low-normal BMI concerns. trial
  • Week 17+ (2.4/2.4 target): Maintenance window; GI often eases vs peak titration but constipation can persist; rate of loss continues over months if adherence holds. trial
  • ~68 weeks (REDEFINE primary): Primary Phase 3 efficacy window; individual curves depend on adherence, dose holds, lifestyle, and baseline. trial
  • ~84 weeks (REDEFINE 4): Longer open-label head-to-head window vs tirzepatide; still continuous weekly use, not a short blast. trial

Around the dose 8

  • Clock: Trials use once-weekly administration. Existing forum notes describe a same-weekday habit and morning/evening choices around nausea, including night placement to sleep through part of the first 24 hours. That preference is not a measured gastric-emptying peak or a proven superior time. forumtrial
  • Food: Existing discussions describe protein-first meals, smaller plates, and vomiting after greasy or spicy shot-day meals. A blinded first-week participant also described fullness, burps, hiccups and reflux. These are reported food/tolerability contexts, not a validated meal protocol. forum
  • Training: Existing discussion links strong satiety with reduced protein intake and lean-mass concern; lifting, shakes or eggs appear as reported responses. These are community practices, not individualized training, diet or dosing instructions. forum
  • After-dose discussion: Existing notes describe walks, water and remaining at an already effective paired step instead of adding milligrams when appetite is strongly suppressed. Those are reported choices, not validated response or dose-hold instructions. forum
  • Alcohol / event-day discussion: Existing notes describe shifting the weekly injection after a wedding or wine dinner. This is a forum habit, not evidence of a known gastric-emptying peak or a safer timing strategy. forum
  • Blend vs two pins: Novo’s dual-chamber pen exists because the two peptides want different pH. 2025–26 r/CagriSema still fights pre-blended research vials vs two separate shots. forumtrial
  • First-exposure reports: Existing notes contrast reported 1.2–2.5 mg blend exposures with paired 0.25/0.25 mg discussion and describe severe vomiting. Amounts and product identity are uncertain; the inspected Help thread does not confirm the suspected overdose or establish a safe starting amount. forum
  • Post-dose reports: Trial participants and self-experimenters describe nausea, fatigue, or brain fog concentrated around the first day after a weekly dose, with substantial person-to-person variation. forumanecdote

Cycles people discuss 8

  • Study structure: Clinical programs use multi-week paired escalation followed by maintenance. Forum users also discuss slower escalation or down-titration, but those reports are not individualized instructions. forumtrial
  • Community “research cycle” windows: Some planning pages discuss 12–24 week windows for tolerability/efficacy sampling or shorter 8–12 week titration-only tests — these will understate full 68-week mean losses. forum
  • Hold-versus-escalate discussion: Existing notes describe remaining at a lower paired step when appetite effects are already strong, and GI problems while pursuing 2.4/2.4 mg. Trial flexibility and forum choices do not establish a personal hold-or-escalate rule. forumtrial
  • Stopping discussion: Existing community notes describe returning appetite, concern about regain, and preferences for slow paired down-titration rather than abrupt stopping; these are not validated stopping instructions. forum
  • Restart discussion: Existing notes describe lower paired amounts such as 0.25/0.25 or 0.5/0.5 mg after a gap, and renewed GI problems after returning directly to a prior maximum. These are reports, not an established restart rule. forum
  • Not a short PED cycle: Clinical model is chronic once-weekly therapy over many months (and potentially years), not a 4–8 week blast. trial
  • Off-treatment follow-up in protocols: REDEFINE designs included multi-week off-treatment observation after the treatment period — residual pharmacologic effect fades over weeks given multi-day half-lives. trial
  • Phase 3 time-on: REDEFINE 1/2 = 68 weeks treatment framing; REDEFINE 4 = ~84 weeks head-to-head; cardiovascular outcomes (REDEFINE 3) and longer maintenance trials (e.g., REDEFINE 11 talk) extend continuous-use evidence further. trial

Timing 8

  • Steady state: Multi-week build on weekly dosing; early weeks understate later exposure for both peptides. forum
  • After stop: Appetite/weight drift back over weeks as both clear across multiple half-lives; not overnight washout. forum
  • Injection-day timing: Same weekday preferred for adherence; clock-hour is less critical than consistency given multi-day PK. forum
  • Cagrilintide half-life (Phase 1b coadmin): ~159–195 hours (~6.6–8.1 days) across 0.16–4.5 mg bands — supports once-weekly dosing. trial
  • Semaglutide half-life (same Phase 1b coadmin): ~145–165 hours with median tmax ~12–24 h. trial
  • Cagrilintide tmax: Median ~24–72 hours post-SC — delayed peak, not same-hour kick. trial
  • Why weekly co-dosing works: Both components have multi-day half-lives and fatty-acid–extended exposure profiles compatible with same-day once-weekly administration. trial
  • Cagrilintide half-life (other PK framing): ~180–184 hours / ~7–8 days commonly cited in mono and combo summaries. trial

More on what it is 8

  • Why people care: Dual-pathway fat-loss candidate after mono GLP-1s; Phase 3 REDEFINE weight-loss headlines in the ~20–23% range and head-to-head drama vs tirzepatide keep forums and obesity-news cycles loud. forum
  • Source gap: Trial dual-chamber / fixed-dose product ≠ informal two-vial research stacks or pre-blended research-chem “CagriSema” vials on purity, fill accuracy, ratio fidelity, or titration device. forum
  • Mechanism (plain): Cagrilintide hits amylin/calcitonin pathways for meal-stop satiety, smaller portions, and slowed gastric emptying; semaglutide hits GLP-1 for appetite, emptying, glucose-dependent insulin signaling, and class weight effects — additive rather than redundant in REDEFINE active-control arms. trial
  • Evidence base: Large human Phase 3 (REDEFINE 1/2/4; REIMAGINE program) plus Phase 1b coadmin PK/PD and Phase 2 mono/combo work — denser evidence than almost any gray-market “stack.” trial
  • Not this: Not a stimulant, not a GH secretagogue, not mono Wegovy/Ozempic alone, not mono cagrilintide alone, not tirzepatide (GIP/GLP-1), not retatrutide (triple), not oral CagriSema. trial
  • Estimand literacy: Headline “22.7%” (trial-product / if-adhere) vs “20.4%” (treatment-policy / closer to ITT) answer different questions — always check which number a post is quoting. trial
  • What it is: Novo Nordisk investigational once-weekly fixed-dose combination of cagrilintide 2.4 mg (long-acting amylin analogue / DACRA-class framing) plus semaglutide 2.4 mg (GLP-1 RA), developed for chronic weight management (REDEFINE) and type 2 diabetes (REIMAGINE). trial
  • Regulatory status (research date framing): NDA filed to FDA for weight management (Dec 2025) based on REDEFINE 1/2; not approved in US/EU as of last research; dual-chamber pen path emphasized after single-chamber co-formulation project was dropped for portfolio reasons. trial

Stacks 9

  • Built-in dual: CagriSema already is cagri + sema — stacking additional GLP-1/GIP/glucagon agonists on top is high GI/duplication-risk talk, not a trial design. forum
  • Vs retatrutide: Forum “which multi-pathway wins” comparisons; no large head-to-head CagriSema vs reta Phase 3 as of last research — cross-trial comparisons are noisy. forum
  • Cagri + tirz (forum adjacent): Some research logs pair cagrilintide with tirzepatide instead of sema as an alternate amylin+incretin stack — not CagriSema, not REDEFINE product. forum
  • Cagri + reta (forum adjacent): Experimental amylin + triple-agonist talk; GI burden and dysesthesia lore appear in stack guides — sparse formal evidence. forum
  • Fat-loss adjacents: AOD-9604, cardarine, cutting stimulants sometimes appear in confounded logs — cannot attribute outcomes to CagriSema alone. forum
  • Anti-nausea / GI tactics: Smaller meals, lower fat/spice during titration, hydration/electrolytes, clinician-directed antiemetics when appropriate — community coping patterns, not a stack claim. forum
  • Lifestyle (trial-standard): Reduced-calorie diet + increased activity in REDEFINE; community emphasizes high protein + resistance training to blunt lean-mass loss. trial
  • Vs tirzepatide: Switch or sequential debates dominate over concurrent stack; REDEFINE 4 favors tirz on mean % loss at 84 weeks while both remain high-efficacy options in discussion. trial
  • Do not casually stack insulin secretagogues or other diabetes meds without clinical context: Hypoglycemia risk rises mainly when combined with insulin/secretagogues in T2D care — trial caution, not DIY license. trial

Access talk 6

  • Three shelves people mix up: investigational dual-chamber pen (trial/future brand), two separate research vials pinned same day, and pre-blended “CagriSema” / “CagriSema Sodium” lyophilized vials. Same nickname, not the same exposure. forum
  • pH / identity fight: r/CagriSema 2025–26 repeats that cagrilintide and semaglutide want different pH, so BAC-water blends can look convenient and still be the wrong product. Separate vials are the “at least I can hold one side” camp. forum
  • Access uncertainty: Severe vomiting was reported after a first exposure to an unverified blend. Replies suspected decimal or unit errors, but the poster disputed the larger volume; delivered amount and cause remain unresolved. Product identity, fill, sterility and concentration add uncertainty. forum
  • No approved product (as of these threads): Novo filed a US NDA 18 Dec 2025 for once-weekly 2.4/2.4; FDA review talk is 2026, launch talk early 2027. Filing ≠ a pharmacy pen. trial
  • Dual-chamber is the real device story: REDEFINE used a dual-chamber single-dose pen. Novo dropped the single-chamber co-formulation project in 2026 “portfolio” notes — that is why DIY one-vial blends are not the trial product. trial
  • Not a shortage-compounding copy. There is no approved CagriSema to copy under the old sema/tirz shortage window. Gray blends are RUO, not 503A copies of a brand. trial

Storage notes 2

  • No mix instructions here: STUDresearch does not list reconstitution, diluent volumes, or syringe unit charts. People reconstitute many different ways and vial labels differ — that content creates more confusion than clarity. forum
  • Storage (general talk only): Unopened research products are usually kept cool, dry, and away from light per the seller label. Anything after first use is product-specific — follow the label, not a universal forum SOP. forum

Watch for 19

  • Lean mass / under-eating: Strong dual satiety can crush protein intake without deliberate high-protein meals and lifting — sarcopenia risk is behavioral as much as pharmacologic. forum
  • Injection-site reactions: Occasional redness/itch as with other weekly SC peptides. forum
  • Source / counterfeit risk: Two-vial or “pre-blended CagriSema” research products can miss 1:1 pairing, under/over-fill, or use dirty powder; investigational status + FDA compounding enforcement climate raises quality stakes. forum
  • Pre-blend ≠ dual-chamber: One-vial “CagriSema” research products skip the pH/device controls Novo could not even co-formulate. Identity, ratio, and fill are unverified. forumtrial
  • Shot-day can’t-leave-bed: 2025 trial-patient interviews described 24-hour nausea, constipation, fatigue, and brain fog after the weekly pin — same class, louder because two emptying pathways. anecdotetrial
  • Unverified blend exposure: Severe vomiting was reported after a first exposure to an unverified blend. Replies suspected decimal or unit errors, but the poster disputed the larger volume; delivered amount and cause remain unresolved. Product identity, fill, sterility and concentration add uncertainty. forum
  • GI (most common): Nausea, vomiting, diarrhea, constipation, abdominal discomfort — class-typical, often titration-linked and mostly mild–moderate in trial summaries. trial
  • REDEFINE 1 GI rates: Any GI AE ~79.6% CagriSema vs ~39.9% placebo; nausea ~55% vs ~12.6%; constipation ~30.7% vs ~11.6%; vomiting ~26.1% vs ~4.1% (mostly transient mild–moderate). trial
  • REDEFINE 2 GI rates: ~72.5% CagriSema vs ~34.4% placebo (mostly mild–moderate). trial
  • AE discontinuation: ~6% CagriSema vs ~3.7% placebo (REDEFINE 1 public summaries; some reports ~5.9% vs ~3.5%); ~8.4% vs ~3.0% (REDEFINE 2). trial
  • Vs sema alone: Meta-analytic and early combo work found higher GI/vomiting burden with the combination than semaglutide alone in some analyses. trial
  • Hypoglycemia: Mainly when combined with insulin or insulin secretagogues; low standalone rates without diabetes meds. trial
  • Thyroid C-cell / MTC–MEN2 label-class caution: Semaglutide-component class warnings (personal/family MTC or MEN2) are routinely carried into community risk lists for any sema-containing stack. trial
  • Gastroparesis / severe GI disease: Delayed emptying from both pathways makes severe baseline motility disease a common clinical exclusion-style caution. trial
  • Pregnancy / breastfeeding: Not studied as a casual research stack; obesity-drug class generally avoids use in pregnancy. trial
  • Not risk-free because “natural amylin + famous GLP-1”: Dual pathway multiplies GI exposure; large trials still show single-digit but real discontinuation and class rare events. trial
  • NDA is not a green light. 2026 FDA-decision headlines are review theater. Gray vials remain gray. trial
  • REDEFINE 4 tolerability framing: Sponsor described GI AEs as mostly mild–moderate and diminishing over time, consistent with GLP-1 RA class (detailed rate tables in full publications when available). trial
  • Gallbladder / pancreatitis: Rare class cautions on GLP-1-pathway agents — acute abdominal pain protocols apply in clinical framing. trial

Updated: 2026-09-01

Evidence mix More trial/lab tags than forum tags Full: every bullet (trial + community). Use Scan for a faster bro-science read.
↑ Back to top

All STUDresearch topics →